The efficacy of Zevtera in treating SAB was established through a randomised, controlled, double-blind, multinational, multicentre clinical trial. Credit: Gorodenkoff / Shutterstock.com.
The approval of Zevtera for paediatric CABP patients was based on the adult CABP trial results and a study involving 138 paediatric subjects with pneumonia.
FDA Center for Drug Evaluation and Research anti-infectives director Peter Kim stated: “The FDA is committed to fostering new antibiotic availability when these prove safe and effective, and Zevtera will provide an additional treatment option for serious bacterial infections.
“The FDA will continue our important work in this area as part of our efforts to protect public health.”